Apremilast

證據等級: L5

預測適應症: 0 個

---

目錄

1. Apremilast
2. Apremilast: Evidence Pack Incomplete — Awaiting TxGNN Prediction Output
   1. One-Sentence Summary
   2. Quick Overview
   3. Why a Full Evaluation Cannot Proceed
   4. Safety Considerations
   5. Conclusion and Next Steps
   6. Disclaimer

---

## 藥師評估報告

The txgnn-pipeline skill covers pipeline operations, not report generation. I'll proceed directly with generating the evaluation report from the Evidence Pack.

---

Analyzing the Evidence Pack for APREMILAST (DB05676):

• predicted_indications: Empty array — no TxGNN predictions were produced
• original_indications: Empty — not populated in this pack
• original_moa: [Data Gap]
• taiwan_regulatory: Not marketed, 0 licenses
• safety: All [Data Gap]
• meta.inputs_received: Only ["drugbank"] — TxGNN prediction step not completed

Given these constraints, per the output rules (no [Data Gap], omit empty sections), the report below reflects only what the Evidence Pack actually contains.

---

Apremilast: Evidence Pack Incomplete — Awaiting TxGNN Prediction Output

One-Sentence Summary

Apremilast (DrugBank ID: DB05676) is a drug with no original indications recorded in this Evidence Pack. The TxGNN prediction step has not been completed — no new indications have been predicted for this compound. This report cannot proceed to a full repurposing evaluation until the prediction pipeline is run and evidence is collected.

---

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack
Predicted New Indication	No predictions generated
TxGNN Prediction Score	N/A
Evidence Level	Cannot be determined
Taiwan Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

---

Why a Full Evaluation Cannot Proceed

The Evidence Pack for Apremilast is missing three foundational inputs required for repurposing analysis:

1. No TxGNN predictions (predicted_indications is empty). The meta.inputs_received field shows only "drugbank" was ingested — the knowledge graph embedding and disease-link prediction steps have not been run for this compound.

2. No mechanism of action data. Without MOA, it is not possible to reason about mechanistic plausibility for any candidate indication, nor to assess whether the drug's target biology overlaps with potential new disease areas.

3. No original indication on record. The Evidence Pack contains an empty original_indications array, which prevents the standard "anchor indication → predicted indication" reasoning chain from being constructed.

Until these gaps are closed, no sections on clinical trial evidence, literature support, or mechanistic rationale can be generated.

---

Safety Considerations

Please refer to the package insert for safety information.

---

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is structurally incomplete — TxGNN has not produced any predicted indications for Apremilast, and the foundational drug-level data (original indication, MOA) required for repurposing evaluation is absent. There is no evidence base to evaluate at this stage.

To proceed, the following is needed:

• Run the TxGNN prediction pipeline for Apremilast (DB05676) against the full disease node set; populate predicted_indications with ranked candidates, scores, and supporting evidence
• Retrieve MOA from DrugBank (DG002, severity: High) — query DrugBank API for mechanism of action, target proteins, and pharmacological class
• Retrieve Taiwan package insert warnings and contraindications (DG001, severity: Blocking) — download and parse the TFDA package insert PDF to unblock the S1 safety screening step
• Populate original_indications — cross-reference DrugBank approved indications and any existing regulatory filings to establish the anchor indication before running the repurposing chain

  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---